



LMA International NV

26 November 2007

Announcement to the Singapore Exchange

GERMAN COURT ISSUES PRELIMINARY INJUNCTION AGAINST AMBU

- Move is to prevent Ambu from the continued marketing of an infringing airway device which violates earlier court ruling

Mainboard-listed LMA International NV (“LMA”), the global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, has obtained a preliminary injunction against Ambu A/S and Ambu Deutschland GmbH (“Ambu”) from the District Court of Dusseldorf, Germany, to prevent the continued marketing of the original design of the Ambu Aura40 airway device, which violated an earlier judgment passed by that Court.

On 22 August 2006, the District Court of Dusseldorf determined that the original design of the Ambu Aura40™ airway device infringes LMA's European Patent EP 1119386B1 and German Utility Model DE 29924738 and ordered Ambu to cease and desist from offering, selling or using the infringing devices in Germany. Ambu has appealed against that judgment. (Refer to LMA announcement on 23 August 2006 - “LMA DEUTSCHLAND WINS PATENT INFRINGEMENT CASE AGAINST AMBU IN GERMANY”)

The infringing devices were observed at Ambu’s stand at MEDICA 2007 in Dusseldorf, Germany. MEDICA is the world’s largest trade fair for medical devices.

LMA International NV

PO Box 862, Osprey House, Old Street, Jersey, Channel Islands JE4 2ZZ

ENDS

FOR FURTHER INFORMATION, PLEASE CONTACT:

Maria Gianoutsos, LMA International NV, +44 (0)1923 841756

Jeffrey Fang, Gavin Anderson & Company, Singapore, +65 9838 5636

NOTES:

LMA International NV

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.

LMA™ Airways

For over 20 years, The Laryngeal Mask Company Limited has been making advances in airway design and technology which have impacted directly on patient safety and comfort. British anaesthetist Dr Archie Brain designed the first LMA™ airway in 1988. Since then, LMA™ airways have been used over 200 million times around the world and are supported by over 2,500 published references. The LMA™ airway has become the most well-known and respected supraglottic airway device worldwide, with a full range of products designed for specialist clinical needs including routine anaesthesia, PPV, ENT surgery, the difficult airway and emergency situations.

LMA Patent Portfolio

LMA has an extensive patent portfolio that protects the key products in the LMA™ range, as well as new products currently under development. The Company's portfolio comprises an estimated 335 granted and pending patents worldwide, the majority of which have a significant unexpired term. Of the Company's granted patents, the earliest expiry date is 2008, and the latest is around 2025.